- Home
- TXG vs ATRC Comparison
TXG vs ATRC Comparison
Compare TXG & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- ATRC
- Stock Information
- Founded
- TXG 2012
- ATRC 2000
- Country
- TXG United States
- ATRC United States
- Employees
- TXG N/A
- ATRC N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- ATRC Medical/Dental Instruments
- Sector
- TXG Industrials
- ATRC Health Care
- Exchange
- TXG Nasdaq
- ATRC Nasdaq
- Market Cap
- TXG 1.7B
- ATRC 1.6B
- IPO Year
- TXG 2019
- ATRC 2005
- Fundamental
- Price
- TXG $13.36
- ATRC $35.45
- Analyst Decision
- TXG Buy
- ATRC Strong Buy
- Analyst Count
- TXG 11
- ATRC 10
- Target Price
- TXG $13.41
- ATRC $49.60
- AVG Volume (30 Days)
- TXG 3.6M
- ATRC 731.1K
- Earning Date
- TXG 08-07-2025
- ATRC 07-29-2025
- Dividend Yield
- TXG N/A
- ATRC N/A
- EPS Growth
- TXG N/A
- ATRC N/A
- EPS
- TXG N/A
- ATRC N/A
- Revenue
- TXG $644,466,000.00
- ATRC $499,946,000.00
- Revenue This Year
- TXG N/A
- ATRC $14.63
- Revenue Next Year
- TXG $5.60
- ATRC $12.62
- P/E Ratio
- TXG N/A
- ATRC N/A
- Revenue Growth
- TXG 2.02
- ATRC 16.28
- 52 Week Low
- TXG $6.78
- ATRC $22.81
- 52 Week High
- TXG $24.76
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- TXG 55.08
- ATRC 56.46
- Support Level
- TXG $12.85
- ATRC $34.91
- Resistance Level
- TXG $14.22
- ATRC $36.96
- Average True Range (ATR)
- TXG 0.94
- ATRC 1.61
- MACD
- TXG -0.09
- ATRC 0.07
- Stochastic Oscillator
- TXG 52.02
- ATRC 59.45
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.